

Journal Information

Journal Title	THERAPEUTIC INNOVATION & REGULATORY SCIENCE
Publisher	SPRINGER HEIDELBERG
ISSN	2168-4790
E-ISSN	2168-4804
Database	Clarivate
Domain	Health Sciences, Life Sciences, Physical Sciences, Social Sciences

Classification History

Year	A+	A	B	C
2026		✓	✓	
2025		✓	✓	
2024		✓	✓	
2023		✓	✓	
2021/2022		✓	✓	
2020		✓	✓	
2019		✓	✓	
2018		✓		

Classification: The table above shows all journal classifications recorded for each classification year in the Green Journals database. A journal may have more than one classification in the same year.

Recent Articles

Post-marketing Safety Assessment in the ICH M14 Era: An International Comparison of Real-World Data Utilization Within Risk Management Plans in the European Union, Japan, and the Republic of Korea 2026-10-28 Authors: Seung-Hun You, Hongsock Kim, Hyounggyoon Yoo et al. DOI: 10.1007/s43441-026-01068-x
Leveraging Regulatory Reliance to Streamline Management of CMC Post-Approval Changes: Industry insights from Multi-Country Reliance Pilots 2026-10-24 Authors: Mónica Perea-Vélez, Marie Kirman, Anjana Patel et al. DOI: 10.1007/s43441-026-01051-6
Japanese Patient Enrollment in Multi-regional Clinical Trials for New Drug Applications in Japan: Current Status and Related Factors 2026-10-23 Authors: Ito Furukawa, Mamoru Narukawa DOI: 10.1007/s43441-026-01069-w
The Role of Digital Twins in Clinical Trials: A New Perspective on Methodological and Statistical Challenges 2026-10-23 Authors: Fatma Nur Cicin DOI: 10.1007/s43441-026-01067-y
Investigator-Initiated Trials as a Clinical Development Approach for Orphan Drugs Compared with Industry-Sponsored Trials in Japan 2026-10-23 Authors: Shingo Yamaguchi, Eiji Nakatani, Ryuta Asada DOI: 10.1007/s43441-026-01063-2

<p>Accelerated Registration of a New Anti-infective Combination in ASEAN Markets: Experience, Insights and Learnings on the ASEAN Joint Assessment (ASEAN JA)</p> <p>2026-10-22</p> <p>Authors: Paul Marvin Quizon, Patriz Miga Lintag-Raymundo, Wan Lee Chow et al.</p> <p>DOI: 10.1007/s43441-026-01070-3</p>
<p>Analytical Advances and Evidence-Proportionate Biosimilar Development</p> <p>2026-10-21</p> <p>Authors: Ryosuke Kuribayashi, Miya Kawasaki, Kanoko Goto</p> <p>DOI: 10.1007/s43441-026-01065-0</p>
<p>A Pragmatic Implementation Framework for Phase 2 Trials with Invasive Endpoints: Estimands, Missing Outcomes, and Decision-Ready Evidence</p> <p>2026-10-21</p> <p>Authors: Dang Anh Tuan</p> <p>DOI: 10.1007/s43441-026-01066-z</p>
<p>The Inflation Reduction Act’s Modeled Impacts upon Late-Stage R&D</p> <p>2026-10-20</p> <p>Authors: Harry P. Bowen, Gwen O’Loughlin, Claire Schleicher et al.</p> <p>DOI: 10.1007/s43441-026-01061-4</p>
<p>Comparison of Labeled Dosages Between Japan and the United States for Drugs Approved in Japan from 2020 to 2025</p> <p>2026-10-20</p> <p>Authors: Takashi Funatogawa, Akihiro Yoshida</p> <p>DOI: 10.1007/s43441-026-01064-1</p>